IDH1 and glioblastoma: However, the notable prevalence of targetable MAPK alterations and the slightly more favorable survival rate compared to typical IDH-wildtype glioblastomas suggest that recognizing these tumors, at least provisionally, as a molecular subtype of IDH-wildtype glioblastomas may be valuable.